1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity.
Clark RD,
Ray NC,
Williams K,
Blaney P,
Ward S,
Crackett PH,
Hurley C,
Dyke HJ,
Clark DE,
Lockey P,
Devos R,
Wong M,
Porres SS,
Bright CP,
Jenkins RE,
Belanoff J.
Corcept Therapeutics, 149 Commonwealth Avenue, Menlo Park, CA 94025, USA.
Addition of the 4-fluorophenylpyrazole group to the previously described 2-azadecalin glucocorticoid receptor (GR) antagonist 1 resulted in significantly enhanced functional activity. SAR of the bridgehead substituent indicated that whereas groups as small as methyl afforded high GR binding, GR functional activity was enhanced by larger groups such as benzyl, substituted ethers, and aminoalkyl derivatives. GR antagonists with binding and functional activity comparable to mifepristone were discovered (e.g., 52: GR binding K(i) 0.7 nM; GR reporter gene functional K(i) 0.6 nM) and found to be highly selective over other steroid receptors. Analogues 43 and 45 had >50% oral bioavailability in the dog.
PMID: 18226897 [PubMed - indexed for MEDLINE]